

Advances in Immunity and Cancer Therapy

Advances in Immunity and Cancer Therapy

Series Editor: P.K. Ray

Editorial Advisory Committee

Tibor Borsos
Frederick, Maryland, U.S.A.

Sharad Deodhar
Cleveland, Ohio, U.S.A.

Hans J. Gurland
Munich, West Germany

Sudhir Gupta
Irvine, California, U.S.A.

Ronald B. Herberman
Bethesda, Maryland, U.S.A.

Lucien Israel
Bobigny, France

Felix Milgrom
Buffalo, New York, U.S.A.

Donald Morton
Los Angeles, California, U.S.A.

David Naor
Jerusalem, Israel

Robert K. Oldham
Franklin, Tennessee, U.S.A.

V. Ramalingaswami
New Delhi, India

Peter Reizenstein
Stockholm, Sweden

F.A. Salinas
Vancouver, Canada

G.P. Talwar
New Delhi, India

Hamao Umezawa
Tokyo, Japan

Advances in Immunity and Cancer Therapy

Volume 2

Edited by P.K. Ray



Springer-Verlag
New York Berlin Heidelberg Tokyo

P.K. RAY
Director, Industrial Toxicology
Research Centre
Mahatma Gandhi Marg
Lucknow, 226001, India

With 8 Figures

ISSN: 0178-2134

©1986 by Springer-Verlag New York Inc.
Softcover reprint of the hardcover 1st edition 1986

All rights reserved. No part of this book may be translated or reproduced in any form without written permission from Springer-Verlag, 175 Fifth Avenue, New York, New York 10010, U.S.A. The use of general descriptive names, trade names, trademarks, etc. in this publication, even if the former are not especially identified, is not to be taken as a sign that such names, as understood by the Trade Marks and Merchandise Marks Act, may accordingly be used freely by anyone.

While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Typeset by Publishers Service, Bozeman, Montana.

9 8 7 6 5 4 3 2 1

ISBN-13:978-1-4613-9560-7 e-ISBN-13:978-1-4613-9558-4
DOI: 10.1007/978-1-4613-9558-4

Preface

The rapid and continuous upsurge of interesting data in the subject of tumor immunology necessitates the publication of an annual series to furnish the updated materials to the students, researchers, and clinicians in this rapidly advancing field. Concepts and methodologies are ever changing. Also, current research in tumor immunology promises to offer breakthroughs in the future. Important is the need to communicate to the right people the exact role of immunodiagnostic methods and immunological intervention in cancer prevention and treatment. The role of immunotherapy in combination with conventional modalities of treatment needs to be understood in its proper perspective. Oncogene, interferon, lymphokines, monoclonal antibodies, natural killer cells, platelet-mediated cytotoxicity of antibody-coated target cells, suppressor cells, platelet-derived factors, plasma-blocking factors, control of suppressor cell function, abrogation of plasma-blocking factors, and so forth, are some of the areas that are continually advancing. Progress in these areas will have implication in cancer therapy. Further, it is already understood that if immunocompetence of the host can be maintained at a reasonably good level, there exists the potential to increase the therapeutic indexes of conventional modalities of treatment. This series will attempt to present updated information in all these areas based on contributed and solicited articles.

P. K. R.

Contents

Chapter 1	Suppressor Cells and Malignancy	1
	<i>David Naor and Jonathan S. Duke-Cohan</i>	
Chapter 2	Abnormality in Immunoregulatory Cells in Human Malignancies	131
	<i>Sudhir Gupta</i>	
Chapter 3	Tumor Growth Versus Fetal Development—Similarities and Confusions	155
	<i>P.K. Ray and Sandip Saha</i>	
Chapter 4	Prognostic and Pathogenetic Implications of Immune Complexes in Human Cancer	189
	<i>F.A. Salinas and K.H. Wee</i>	
Chapter 5	Platelet and Granulocyte Transfusions in Cancer Patients	211
	<i>Janice P. Dutcher</i>	
Chapter 6	Specificity and Use of Antisera Produced Against Anticancer Drugs	251
	<i>Kunio Fujiwara and Tsunehiro Kitagawa</i>	
Index		293

Contributors

JONATHAN S. DUKE-COHAN
The Lautenberg Center for General
and Tumor Immunology
The Hebrew University
Hadassah Medical School
Jerusalem, Israel

JANICE P. DUTCHER
Albert Einstein College of Medicine
Bronx, New York, U.S.A.

KUNIO FUJIWARA
Faculty of Pharmaceutical Sciences
Nagasaki University
Nagasaki, Japan

SUDHIR GUPTA
Division of Basic and Clinical
Immunology
University of California
Irvine, California, U.S.A.

TSUNEHIRO KITAGAWA
Faculty of Pharmaceutical Sciences
Nagasaki University
Nagasaki, Japan

DAVID NAOR
The Lautenberg Center for General
and Tumor Immunology
The Hebrew University
Hadassah Medical School
Jerusalem, Israel

P.K. RAY
Industrial Toxicology Research
Centre
Lucknow, India

SANDIP SAHA
Department of Surgery and
Microbiology
The Medical College of Pennsylvania
and Hospital
Philadelphia, Pennsylvania, U.S.A.

F.A. SALINAS
Advanced Therapeutics Department
Cancer Control Agency of British
Columbia
Vancouver, British Columbia, Canada

K.H. WEE
Advanced Therapeutics Department
Cancer Control Agency of British
Columbia
Vancouver, British Columbia, Canada